Literature DB >> 4151092

Agranulocytosis associated with sulphasalazine therapy.

P Cochrane, P Atkins, S Ehsanullah.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4151092      PMCID: PMC2495754          DOI: 10.1136/pgmj.49.575.669

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  9 in total

1.  HEMOLYTIC ANEMIA SECONDARY TO SALICYLAZOSULFAPYRIDINE THERAPY.

Authors:  M D GARDNER; J A BARGEN
Journal:  JAMA       Date:  1964-10-05       Impact factor: 56.272

2.  HUMAN ACETYLATION POLYMORPHISM.

Authors:  D A EVANS; T A WHITE
Journal:  J Lab Clin Med       Date:  1964-03

3.  THE OCCURRENCE OF HEINZ BODIES DURING AZULFIDINE TREATMENT OF ULCERATIVE COLITIS.

Authors:  L E BOETTIGER; L ENGSTEDT; R LAGERCRANTZ; A NYBERG
Journal:  Gastroenterologia       Date:  1963

4.  An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis.

Authors:  J E LENNARD-JONES; A J LONGMORE; A C NEWELL; C W WILSON; F A JONES
Journal:  Gut       Date:  1960-09       Impact factor: 23.059

5.  Studies of the bone marrow in immunological granulocytopenia; following administration of salicylazosulfapyridine.

Authors:  R S EVANS; W P FORD
Journal:  AMA Arch Intern Med       Date:  1958-02

6.  Simplified method for determining acetylator phenotype.

Authors:  H Schröder
Journal:  Br Med J       Date:  1972-08-26

7.  Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.

Authors:  H Schröder; D A Evans
Journal:  Gut       Date:  1972-04       Impact factor: 23.059

8.  Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis.

Authors:  J R Collins
Journal:  South Med J       Date:  1968-04       Impact factor: 0.954

9.  Agranulocytosis associated with sulphasalazine ('Salazopyrin') therapy.

Authors:  J L THIRKETTLE; K R GOUGH; A E READ
Journal:  Lancet       Date:  1963-06-29       Impact factor: 79.321

  9 in total
  4 in total

1.  Sulphasalazine induced agranulocytosis in a patient with rheumatoid arthritis.

Authors:  P T Murphy; J R O'Donnell
Journal:  Ir J Med Sci       Date:  1990-06       Impact factor: 1.568

Review 2.  Sulfasalazine. Adverse effects and desensitization.

Authors:  S L Taffet; K M Das
Journal:  Dig Dis Sci       Date:  1983-09       Impact factor: 3.199

3.  Sulfasalazine-induced DRESS and severe agranulocytosis successfully treated by granulocyte colony-stimulating factor.

Authors:  Neila Fathallah; Raoudha Slim; Salaheddine Rached; Wissem Hachfi; Amel Letaief; Chaker Ben Salem
Journal:  Int J Clin Pharm       Date:  2015-04-09

Review 4.  Clinical pharmacokinetics of sulphasalazine.

Authors:  K M Das; R Dubin
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.